CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells
Yiyi Pu, Dongmei Yan, Linglan Tu, Liyan Cheng, Jie Yu, Zhuduo Li, Xiaoliang Zheng, Xinbao Wang
Journal：DISEASE MARKERS
IF：3.46
DOI：10.1155/2022/6907057
PMID：35308136
Published：2022-03-11
research field：肿瘤学分子生物学生物医学工程癌症诊断
Abstract
Background. 5-Fluorouracil (5-FU) has been widely applied in treating cancers. However, its usage is largely limited in hepatocellular carcinoma (HCC), due to acquired resistance. Here, we aim to identify target proteins and investigate their roles in 5-FU sensitivity of HCC cells. Methods. Mass spectrometry (MS) proteomics was performed on 5-FU-resistant cell line (BEL7402/5-FU) and its parental cell line (BEL7402) with 5-FU treatment. In order to identify potential targets, we compared the proteomics between two cell line groups and used bioinformatics tools to select hub proteins from all differentially expressed proteins. Results. We finally focused on a group of cell cycle-related kinases (CDKs). By CCK8 assay, we confirmed that the CDK inhibitor significantly decreased the IC50 of 5-FU-resistant cells. Conclusions. Our study verified that CDK inhibition can reverse 5-FU resistance of HCC cells.
本文使用的Yeasen产品
